Sun Meihua, Zhang Yanqing, Guo Anbing, Xia Zongting, Peng Lijun
School of Clinical Medicine, Weifang Medical University, Weifang, Shandong, China.
Department of Gastroenterology, Linyi People's Hospital, Linyi, Shandong, China.
J Clin Transl Hepatol. 2024 Feb 28;12(2):191-200. doi: 10.14218/JCTH.2023.00231. Epub 2023 Oct 30.
Liver fibrosis is a reversible condition that occurs in the early stages of chronic liver disease. To develop effective treatments for liver fibrosis, understanding the underlying mechanism is crucial. The NOD-like receptor protein 3 (NLRP3) inflammasome, which is a part of the innate immune system, plays a crucial role in the progression of various inflammatory diseases. NLRP3 activation is also important in the development of various liver diseases, including viral hepatitis, alcoholic or nonalcoholic liver disease, and autoimmune liver disease. This review discusses the role of NLRP3 and its associated molecules in the development of liver fibrosis. It also highlights the signal pathways involved in NLRP3 activation, their downstream effects on liver disease progression, and potential therapeutic targets in liver fibrosis. Further research is encouraged to develop effective treatments for liver fibrosis.
肝纤维化是一种发生在慢性肝病早期的可逆病症。要开发出有效的肝纤维化治疗方法,了解其潜在机制至关重要。NOD样受体蛋白3(NLRP3)炎性小体是固有免疫系统的一部分,在各种炎症性疾病的进展中起关键作用。NLRP3激活在包括病毒性肝炎、酒精性或非酒精性肝病以及自身免疫性肝病在内的各种肝病发展中也很重要。本综述讨论了NLRP3及其相关分子在肝纤维化发展中的作用。它还强调了NLRP3激活所涉及的信号通路、它们对肝病进展的下游影响以及肝纤维化中的潜在治疗靶点。鼓励开展进一步研究以开发有效的肝纤维化治疗方法。